<DOC>
	<DOCNO>NCT01622062</DOCNO>
	<brief_summary>The purpose study ass 4-site `` one-week '' post-exposure prophylaxis ( PEP ) regimen possible alternative 2-site updated Thai Red Cross ( TRC ) PEP regimen . Primary objective : - To demonstrate PEP use new `` one-week , 4-site '' ( 4-4-4-0-0 ) intradermal PEP regimen ( without rabies immunoglobulin ) , non-inferior PEP use updated TRC ( 2-2-2-0-2 ) ID PEP regimen rabies immunoglobulin term seroprotection rate Day 14 . Secondary objective : - To describe immune response group Day 0 , Day 14 Day 90 . - To describe rabies virus-neutralizing antibody persistence 5 year completion PEP group . - To describe immune response induce single-visit 4-site intradermal ( ID ) booster vaccination group Year 5 . - To describe safety profile treatment group primary booster vaccination .</brief_summary>
	<brief_title>Immunogenicity Safety Verorab® `` One-week '' Intradermal Post-exposure Prophylaxis Regimen</brief_title>
	<detailed_description>Study participant receive either Verorab® , without Favirab® , accord WHO categorization contact , depend group allocation , Day 0 28 , booster vaccine 5 year post-primary vaccination .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>For patient : Patient age ≤50 year , WHO category II III contact happen within 48 hour appearance site . For adult : Informed consent form sign date . Able attend schedule visit comply trial procedure . For child : For child 18 year age , informed consent form sign dated parent ( ) another legally acceptable representative . For child 18 year , assent form inform consent form sign dated appropriate agerange patient , accord country specific institution requirement detailed country specific assent form inform consent form . Patient parent/guardian able attend schedule visit comply trial procedure . For patient : Receipt chloroquine medication use malaria chemoprophylaxis , without antimalarial treatment , 4 week ( duration antimalarial course ) part treatment receive within 2 week vaccination . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial immunization Planned participation another clinical trial present trial period Receipt vaccine 4 week precede first trial vaccination , except influenza vaccination Planned receipt vaccine 4 week follow trial primary booster vaccination Previous immunization rabies time past either trial vaccine immunoglobulin another rabies immunobiological product ( preor postexposure regimen ) Receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B virus , Hepatitis C virus Patient clinical sign encephalitis Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Chronic illness , opinion investigator , stage might interfere trial conduct completion Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator Febrile illness ( temperature ≥38.0°C ) moderate severe acute illness/infection ( accord investigator judgment ) day vaccination Prior history mammal animal bite within past 5 year . For infant toddler : Known personal maternal seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B virus , Hepatitis C virus , report parent/guardian Prior history seizure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rabies</keyword>
	<keyword>Verorab®</keyword>
	<keyword>Favirab®</keyword>
</DOC>